Recent News

• 05.27.2025 - BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
• 05.27.2025 - BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
• 05.27.2025 - BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
• 05.27.2025 - BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
• 05.27.2025 - BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
• 05.12.2025 - BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.12.2025 - BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - 8-K Current report
• 05.01.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 04.03.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.03.2025 - 8-K Current report
• 04.01.2025 - 4 Statement of changes in beneficial ownership of securities